Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161246 · ClinicalTrials.gov registry record · Phase 4
A Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction
A Phase 4 study of Injection Site Discomfort, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06161246: Completed Phase 4 study of Injection Site Discomfort, sponsored by Galderma R&D.
NCT06161246 is a Phase 4 study of Injection Site Discomfort that has completed, run by Galderma R&D. The registered enrollment target is 60 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06161246, a Phase 4 study of Injection Site Discomfort, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, single-center, randomized, split-face, controlled study to assess the effect of comfort intervention on pain during treatment injection compared against non-comfort intervention.
Primary Outcome
Visual Analogue Scale is a 11-point psychometric scale that specifies the level of pain. Subject will be shown a photo of a VAS and verbally report a pain score between 0 and 10, which will be captured by a clinic staff. A score of 0 corresponds to no pain felt and a score of 10 corresponds to very high pain.
Conditions Studied
Interventions
- DEVICE Vibrating Beauty Bar
Study Locations (1)
Illinois
- DeNova Research - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-10-23 |
| Est. Completion | 2024-02-15 |
| Phase | Phase 4 |
What the finished NCT06161246 record still lists
NCT06161246 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Injection Site Discomfort appearing as the primary indexed condition, and to 1 intervention - of which Vibrating Beauty Bar is the first listed.
NCT06161246 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06161246 about?
NCT06161246 is a clinical study titled "A Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction". This is an open-label, single-center, randomized, split-face, controlled study to assess the effect of comfort intervention on pain during treatment injection compared against non-comfort intervention.
What is the current status of trial NCT06161246?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2023-10-23. Estimated completion is 2024-02-15.
What conditions does trial NCT06161246 study?
This clinical trial studies the following conditions: Injection Site Discomfort.
What interventions are being tested in trial NCT06161246?
The interventions under investigation include: Vibrating Beauty Bar (DEVICE).
Who is sponsoring clinical trial NCT06161246?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06161246 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06161246's enrollment target sits among peer trials
60 1125th of 2000 higher than 799 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI